Fennec Pharmaceuticals Inc. (FENC) shareholders
Close on Nov 17, 2026Market cap $476.21MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rosalind Advisors, Inc. Joint filing with Salamon Steven A J (9.40%), Aharon Gil (9.40%) and 1 more | 3,321,333 | 9.60% | 13G (passive) amendment | Jun 30, 2026 |
| Kam Lawrence Joint filing with Sonic Fund II, L.P. (7.60%), Sonic GP LLC (7.60%) | 2,799,959 | 8.20% | 13G (passive) amendment | Dec 31, 2025 |
| Southpoint Master Fund, LP Joint filing with Southpoint Capital Advisors LP (8.00%), Southpoint Capital Advisors LLC (8.00%) and 3 more | 2,744,741 | 8.00% | 13G (passive) amendment | Dec 31, 2025 |
| Orin Hirschman Joint filing with AIGH Capital Management LLC (7.10%) | 2,499,421 | 7.10% | 13G (passive) amendment | Sep 30, 2026 |
| Solas Capital Management, LLC Joint filing with Frederick Tucker Golden (7.20%) | 2,482,198 | 7.20% | 13G (passive) amendment | Mar 31, 2026 |
| Frederick Tucker Golden Joint filing with Solas Capital Management, LLC (5.40%) | 1,889,366 | 5.40% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FENC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 3,188,001 | 9.09% | $34.27M | +279,800 | 12.73% |
| AIGH Capital Management LLC | 2,486,038 | 7.09% | $26.72M | +504,537 | 1.68% |
| Solas Capital Management, LLC | 1,889,366 | 5.39% | $20.31M | −592,832 | 10.88% |
| BlackRock, Inc. | 1,727,069 | 4.93% | $18.57M | +358,893 | 0.00% |
| AWM Investment Company, Inc. | 1,160,296 | 3.31% | $12.47M | +440,161 | 1.08% |
| Vanguard Capital Management LLC | 839,306 | 2.39% | $9.02M | −57,838 | 0.00% |
| Prospect Capital Advisors, LLC | 497,800 | 1.42% | $5.35M | New | 2.43% |
| State Street Corp | 426,004 | 1.21% | $4.58M | +66,949 | 0.00% |
| Geode Capital Management, LLC | 402,566 | 1.15% | $4.33M | +30,828 | 0.00% |
| Jane Street Group, LLC | 233,877 | 0.67% | $2.51M | New | 0.00% |
| Potomac Capital Management, Inc. | 224,400 | 0.64% | $2.41M | – | 1.65% |
| Morgan Stanley | 221,920 | 0.63% | $2.39M | +10,812 | 0.00% |
| Vanguard Portfolio Management LLC | 199,998 | 0.57% | $2.15M | +31,525 | 0.00% |
| Northern Trust Corp | 167,922 | 0.48% | $1.81M | +15,799 | 0.00% |
| Marshall Wace, Llp | 138,758 | 0.40% | $1.49M | New | 0.00% |
| Renaissance Technologies LLC | 134,200 | 0.38% | $1.44M | New | 0.00% |
| Nuveen, LLC | 131,482 | 0.37% | $1.41M | +70,534 | 0.00% |
| Trexquant Investment LP | 119,122 | 0.34% | $1.28M | +67,253 | 0.01% |
| CenterBook Partners LP | 118,582 | 0.34% | $1.27M | New | 0.06% |
| Lion Point Capital, LP | 112,434 | 0.32% | $1.21M | – | 5.78% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 105 | 16M | 46.5% | 25 / 44 | 18 / 8 | 4M | 4M |
| Q1 2026 | 90 | 16M | 46.2% | 16 / 38 | 18 / 20 | 3M | 1M |
| Q4 2025 | 96 | 16M | 44.3% | 20 / 26 | 24 / 8 | 4M | 2M |
| Q3 2025 | 84 | 14M | 39.6% | 11 / 27 | 24 / 5 | 1M | 1M |
| Q2 2025 | 78 | 14M | 38.8% | 16 / 25 | 24 / 6 | 1M | 1M |
| Q1 2025 | 68 | 13M | 38.2% | 9 / 21 | 20 / 3 | 1M | 1M |
| Q4 2024 | 64 | 16M | 45.8% | 13 / 25 | 14 / 12 | 2M | 1M |
| Q3 2024 | 63 | 15M | 42.6% | 8 / 26 | 15 / 8 | 2M | 0M |
| Q2 2024 | 64 | 14M | 41.0% | 17 / 25 | 12 / 17 | 1M | 1M |
| Q1 2024 | 65 | 15M | 41.8% | 14 / 25 | 17 / 5 | 2M | 2M |
| Q4 2023 | 56 | 15M | 43.1% | 7 / 22 | 14 / 6 | 2M | 1M |
| Q3 2023 | 55 | 14M | 40.8% | 3 / 17 | 16 / 4 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
75 funds held FENC in Q2 2026, 70% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of FENC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 815,192 | 2.32% | $8.76M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 750,369 | 2.14% | $8.07M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 316,471 | 0.90% | $3.03M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 266,715 | 0.76% | $2.87M | 0.02% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 149,156 | 0.43% | $1.48M | 0.01% | May 31, 2026 |
| Ultra-Small Company Fund | 108,005 | 0.31% | $1.16M | 1.18% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 97,115 | 0.28% | $1.04M | 0.07% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 85,124 | 0.24% | $915.08K | 0.00% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 70,504 | 0.20% | $674.72K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 50,481 | 0.14% | $542.67K | 0.01% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 33,813 | 0.10% | $323.59K | 0.01% | Jul 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 33,380 | 0.10% | $358.84K | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Growth Index Fund | 27,211 | 0.08% | $292.52K | 0.02% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 19,587 | 0.06% | $194.50K | 0.00% | May 31, 2026 |
| Invesco Russell 2000 Dynamic Multifactor ETF | 18,228 | 0.05% | $181.00K | 0.06% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jeffrey S. Hackman | Chief Executive Officer, Director | 70,844 | 0.20% | Nov 2, 2026 |
| Christiana Marie Cioffi | Chief Strategy Officer | 28,902 | 0.08% | Nov 2, 2026 |
| Pierre Sargis Sayad | Chief Medical Officer | 13,701 | 0.04% | Nov 2, 2026 |
| Terry L. Evans | Chief Commercial Officer | 24,181 | 0.07% | Nov 2, 2026 |
| Robert Andrade | CHIEF FINANCIAL OFFICER | 248,558 | 0.71% | Nov 2, 2026 |
| Marco Maria Brughera | Director | 0 | – | Nov 16, 2026 |
| Jodi A. Cook | Director | – | – | Jun 10, 2026 |
| Khalid Islam | Director | 133,333 | 0.38% | Jun 10, 2026 |
| Chris A. Rallis | Director | 63,077 | 0.18% | Jun 10, 2026 |
| Rosty Raykov | – | 124,411 | 0.35% | Sep 1, 2026 |
| Capital Advisors LLC Southpoint | 10% owner | 3,744,741 | 10.68% | Dec 29, 2025 |
| Southpoint GP, LP | 10% owner | 4,077,214 | 11.63% | Dec 29, 2025 |
| Southpoint GP, LLC | 10% owner | 3,764,082 | 10.73% | Dec 29, 2025 |
| Capital Advisors LP Southpoint | 10% owner | 2,744,741 | 7.83% | Dec 29, 2025 |
| John Smith Clark II | 10% owner | 41,504,000 | 118.36% | Dec 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Marco Maria Brughera Director | Nov 13, 2026 | Sale(10b5-1 plan) | −20,000 | $12.00 | $240.00K | 0 |
| Marco Maria Brughera Director | Nov 13, 2026 | Option exercise | +20,000 | $2.11 | $42.20K | 20,000 |
| Christiana Marie Cioffi Chief Strategy Officer | Oct 31, 2026 | Award | +156 | – | – | 28,902 |
| Pierre Sargis Sayad Chief Medical Officer | Oct 31, 2026 | Award | +168 | – | – | 13,701 |
| Terry L. Evans Chief Commercial Officer | Oct 31, 2026 | Award | +168 | – | – | 24,181 |
| Jeffrey S. Hackman Chief Executive Officer, Director | Oct 31, 2026 | Award | +1,159 | – | – | 70,844 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Oct 31, 2026 | Award | +1,703 | – | – | 248,558 |
| Christiana Marie Cioffi Chief Strategy Officer | Oct 12, 2026 | Award | +3,946 | $5.53 | $21.82K | 28,746 |
| Pierre Sargis Sayad Chief Medical Officer | Oct 12, 2026 | Award | +3,846 | $5.53 | $21.27K | 13,533 |
| Terry L. Evans Chief Commercial Officer | Oct 12, 2026 | Award | +2,326 | $5.53 | $12.86K | 24,013 |
| Jeffrey S. Hackman Chief Executive Officer, Director | Oct 12, 2026 | Award | +2,224 | $5.53 | $12.30K | 69,685 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Oct 12, 2026 | Award | +3,846 | $5.53 | $21.27K | 246,855 |
| Christiana Marie Cioffi Chief Strategy Officer | Sep 30, 2026 | Award | +156 | – | – | 24,800 |
| Pierre Sargis Sayad Chief Medical Officer | Sep 30, 2026 | Award | +168 | – | – | 9,687 |
| Terry L. Evans Chief Commercial Officer | Sep 30, 2026 | Award | +168 | – | – | 21,687 |
| Jeffrey S. Hackman Chief Executive Officer, Director | Sep 30, 2026 | Award | +1,159 | – | – | 67,461 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Sep 30, 2026 | Award | +1,703 | – | – | 243,009 |
| Marco Maria Brughera Director | Sep 15, 2026 | Sale(10b5-1 plan) | −15,545 | $10.29 | $159.96K | 0 |
| Marco Maria Brughera Director | Sep 15, 2026 | Option exercise | +15,545 | $2.11 | $32.80K | 15,545 |
| Rosty Raykov – | Sep 1, 2026 | Sale(10b5-1 plan) | −10,000 | $12.11 | $121.10K | 124,411 |
| Rosty Raykov – | Aug 31, 2026 | Award | +2,778 | – | – | 134,411 |
| Jeffrey S. Hackman Chief Executive Officer, Director | Aug 31, 2026 | Award | +1,159 | – | – | 66,302 |
| Terry L. Evans Chief Commercial Officer | Aug 31, 2026 | Award | +168 | – | – | 21,519 |
| Pierre Sargis Sayad Chief Medical Officer | Aug 31, 2026 | Sale | −12,000 | $12.18 | $146.16K | 9,519 |
| Pierre Sargis Sayad Chief Medical Officer | Aug 31, 2026 | Award | +168 | – | – | 21,519 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Aug 31, 2026 | Award | +1,703 | – | – | 241,306 |
| Christiana Marie Cioffi Chief Strategy Officer | Aug 31, 2026 | Award | +156 | – | – | 24,644 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Aug 28, 2026 | Option exercise | +21,928 | $5.10 | $111.83K | 239,603 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Aug 27, 2026 | Sale(10b5-1 plan) | −75,000 | $11.78 | $883.50K | 217,675 |
| Rosty Raykov – | Aug 3, 2026 | Sale(10b5-1 plan) | −10,000 | $9.58 | $95.80K | 131,633 |
| Pierre Sargis Sayad Chief Medical Officer | Jul 31, 2026 | Award | +168 | – | – | 21,351 |
| Rosty Raykov – | Jul 31, 2026 | Award | +2,778 | – | – | 141,633 |
| Jeffrey S. Hackman Chief Executive Officer, Director | Jul 31, 2026 | Award | +1,159 | – | – | 65,143 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Jul 31, 2026 | Award | +1,703 | – | – | 292,675 |
| Christiana Marie Cioffi Chief Strategy Officer | Jul 31, 2026 | Award | +156 | – | – | 24,488 |
| Terry L. Evans Chief Commercial Officer | Jul 31, 2026 | Award | +168 | – | – | 21,351 |
| Rosty Raykov – | Jul 1, 2026 | Sale(10b5-1 plan) | −9,599 | $10.41 | $99.93K | 138,855 |
| Rosty Raykov – | Jul 1, 2026 | Option exercise | +15,597 | $2.45 | $38.21K | 148,454 |
| Rosty Raykov – | Jul 1, 2026 | Award | +2,778 | – | – | 132,857 |
| Pierre Sargis Sayad Chief Medical Officer | Jun 30, 2026 | Award | +168 | – | – | 21,183 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Jun 30, 2026 | Award | +1,703 | – | – | 290,972 |
| Terry L. Evans Chief Commercial Officer | Jun 30, 2026 | Award | +168 | – | – | 21,183 |
| Christiana Marie Cioffi Chief Strategy Officer | Jun 30, 2026 | Award | +156 | – | – | 24,332 |
| Jeffrey S. Hackman Chief Executive Officer, Director | Jun 30, 2026 | Award | +1,159 | – | – | 63,984 |
| Rosty Raykov Director | Jun 1, 2026 | Option exercise | +15,597 | $2.45 | $38.21K | 139,826 |
| Rosty Raykov Director | Jun 1, 2026 | Sale(10b5-1 plan) | −9,747 | $9.62 | $93.77K | 130,079 |
| Rosty Raykov Director | May 31, 2026 | Award | +2,778 | – | – | 124,229 |
| Robert Andrade CHIEF FINANCIAL OFFICER | May 31, 2026 | Award | +1,703 | – | – | 289,269 |
| Christiana Marie Cioffi Chief Strategy Officer | May 31, 2026 | Award | +156 | – | – | 24,176 |
| Terry L. Evans Chief Commercial Officer | May 31, 2026 | Award | +168 | – | – | 21,015 |
| Jeffrey S. Hackman Chief Executive Officer, Director | May 31, 2026 | Award | +1,159 | – | – | 62,825 |
| Pierre Sargis Sayad Chief Medical Officer | May 31, 2026 | Award | +168 | – | – | 21,015 |
| Chris A. Rallis Director | May 11, 2026 | Sale(10b5-1 plan) | −8,346 | $7.04 | $58.76K | 63,077 |
| Chris A. Rallis Director | May 11, 2026 | Option exercise | +14,344 | $2.44 | $35.00K | 71,423 |
| Rosty Raykov Director | May 1, 2026 | Option exercise | +15,598 | $2.45 | $38.22K | 132,232 |
| Rosty Raykov Director | May 1, 2026 | Sale(10b5-1 plan) | −10,781 | $6.47 | $69.75K | 121,451 |
| Pierre Sargis Sayad Chief Medical Officer | Apr 30, 2026 | Option exercise | +168 | – | – | 20,847 |
| Jeffrey S. Hackman Chief Executive Officer, Director | Apr 30, 2026 | Option exercise | +1,159 | – | – | 61,666 |
| Terry L. Evans Chief Commercial Officer | Apr 30, 2026 | Option exercise | +168 | – | – | 20,847 |
| Rosty Raykov Director | Apr 30, 2026 | Option exercise | +2,778 | – | – | 116,634 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Fennec Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 12,034 shares on Sep 16, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Marco Maria Brughera Director | Sep 15, 2026 | 15,545 | $160.07K | Sep 15, 2026 | Stock Option Exercise |
| Rostislav Raykov Former Director | Sep 1, 2026 | 10,000 | $121.18K | Sep 1, 2026 | Restricted Stock |
| Pierre Sargis Sayad Officer | Aug 31, 2026 | 12,000 | $146.17K | Aug 31, 2026 | Performance Shares |
| Robert Andrade Officer | Aug 27, 2026 | 75,000 | $883.90K | Aug 27, 2026 | Exercised Shares |
| Rostislav Raykov Former Director | Aug 3, 2026 | 10,000 | $95.84K | Aug 3, 2026 | Restricted Stock |
| Rostislav Raykov Director | Jul 1, 2026 | 9,599 | $99.99K | Jul 1, 2026 | Stock Option Exercise |
| Rostislav Raykov Director | Jun 1, 2026 | 9,747 | $93.81K | Jun 1, 2026 | Stock Option Exercise |
| Chris A. Rallis Director | May 11, 2026 | 8,346 | $58.83K | May 11, 2026 | Stock Option Exercise |
| Rostislav Raykov Director | May 1, 2026 | 10,781 | $69.76K | May 1, 2026 | Stock Option Exercise |
| Rostislav Raykov Director | Apr 1, 2026 | 10,946 | $69.07K | Apr 1, 2026 | Stock Option Exercise |
| Rostislav Raykov Director | Mar 2, 2026 | 10,079 | $84.35K | Mar 2, 2026 | Stock Option Exercise |
| Rostislav Raykov Director | Feb 2, 2026 | 10,349 | $80.34K | Feb 2, 2026 | Stock Option Exercise |
| Rostislav Raykov Director | Jan 2, 2026 | 10,312 | $78.47K | Jan 2, 2026 | Stock Option Exercise |
| Rostislav Raykov Director | Dec 5, 2025 | 10,000 | $75.44K | Dec 5, 2025 | Restricted Stock |
| Rostislav Raykov Director | Nov 5, 2025 | 10,000 | $81.08K | Nov 5, 2025 | Restricted Stock |
See a number that looks wrong?